Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Naproxen Cardio Benefit “Not Large Enough” To Back Vioxx Defense – Lancet

This article was originally published in The Tan Sheet

Executive Summary

Naproxen's perceived cardioprotective benefit demonstrated in studies likely is due to coincidence, according to a recent study published in the Lancet
Advertisement

Related Content

FDA’s Graham Casts Doubt On Naproxen Cardioprotection, Vioxx Defense
FDA’s Graham Casts Doubt On Naproxen Cardioprotection, Vioxx Defense
FDA’s Graham Casts Doubt On Naproxen Cardioprotection, Vioxx Defense
Reversal Of Fortune? Vioxx Recall Presents Opportunity For NSAID Makers
Reversal Of Fortune? Vioxx Recall Presents Opportunity For NSAID Makers

Topics

Advertisement
UsernamePublicRestriction

Register

PS097522

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel